Duzofarm tabs 50mg #90

Instruction for Duzofarm

Reed more and buy Duzofarm here

Duzofarm is a vasodilating agent.

Release form and composition

Dosage form - film-coated tablets: round, biconvex, orange (10 pcs. In blisters, in a cardboard box of 3, 6 or 9 blisters).
Composition of 1 tablet:
    active substance: naftidrofuryl oxalate - 50 mg;
    auxiliary components: sodium glycolate starch (type A), copovidone, microcrystalline cellulose, lactose monohydrate, wheat starch, magnesium stearate, colloidal silicon dioxide, crospovidone, talc;
    shell composition: methacrylic acid and ethyl acrylate copolymer, talc, titanium dioxide, macrogol 6000, dibutyl phthalate, sunset yellow dye E110.

Pharmacodynamics

Naphtidrofuril oxalate is a substance that has a vasodilating effect and, as a result, improves cerebral and peripheral circulation.
The drug reduces peripheral vascular resistance and increases cardiac output. However, it does not significantly affect blood pressure and heart rate.
Naphtidrofuril has a vasodilating effect, which is the result of its selective action on 5HT2 receptors of the smooth muscle layer of blood vessels and platelets. Due to vasodilation, there is an improvement in microcirculation in the brain, retina and peripheral tissues.
Also, the drug has an M-anticholinergic effect. Under conditions of ischemia, it causes a decrease in anaerobic metabolism, as a result of which the lactate pyruvate coefficient decreases and the concentration of adenosine triphosphate increases, and the resistance of cells (including the brain) to hypoxia increases.
Duzofarm helps to normalize sleep, reduces episodes of headache and dizziness, improves cognitive function of the brain, as well as blood rheology by increasing the elastic properties of erythrocytes and inhibiting platelet aggregation.

Pharmacokinetics

After oral administration, naftidrofuril is almost completely absorbed from the gastrointestinal tract. Food has virtually no effect on its absorption.
After taking a single dose of 100 mg, the maximum plasma concentration is 0.175 mg / ml and is observed after 45-60 minutes. 24 hours after administration, the concentration in the brain tissues is 3 times higher than in the plasma.
The substance undergoes hepatic recirculation, which is why it is in the plasma for a longer time. The connection with blood proteins is about 80%. Penetrates the blood-brain barrier. There are no data on the penetration of naftidrofuril through the placenta and into breast milk.
The drug is metabolized mainly in the liver by hydrolysis, which is carried out by plasma esterases, with the formation of metabolites, the main studied of which are nafroic acid and diethylaminoethanol. The latter has a stimulating effect on the central nervous system.
It is excreted from the body mainly through the intestines, in small quantities - by the kidneys.
The half-life after taking a single dose of 100 mg is 1–2 hours, after a dose of 200 mg - 3.5 hours.
There are no data on changes in the rate of elimination of naftidrofuril in case of impaired renal or liver function.
Age has no effect on the pharmacokinetic parameters of the drug.

Indications for use

    peripheral circulatory disorders: leg pain at rest, calf muscle cramps, acrocyanosis, paresthesia, intermittent claudication syndrome, Raynaud's syndrome and disease;
    violation of cerebral circulation due to cerebral vascular insufficiency and atherosclerotic lesions of cerebral vessels, especially in elderly patients;
    trophic disorders: diabetic retinopathy, long-term non-healing ulcers.

Contraindications

Absolute:
    tachyarrhythmias;
    arterial hypotension;
    acute stage of myocardial infarction;
    chronic heart failure stage II – III (III – IV in accordance with the functional classification of heart failure of the New York Heart Association NYHA);
    increased convulsive readiness;
    epilepsy;
    acute stage of hemorrhagic stroke;
    lactase deficiency, galactosemia, glucose-galactose malabsorption syndrome;
    age up to 18 years;
    individual intolerance to the drug.
Relative: prostatic hyperplasia, angle-closure glaucoma.

Instructions for use of Duzofarm: method and dosage

Duzofarm tablets are indicated for oral use: they must be swallowed whole with plenty of water (at least 1 glass).
For disorders of cerebral circulation, the recommended daily dose is 300-600 mg in 3 divided doses.
For peripheral circulatory disorders, 200 mg is prescribed 2-3 times a day.
Long-term treatment. The duration is determined individually, depending on the individual clinical situation.
No dose adjustment is required for hepatic or renal impairment.

Side effects

When taken in a daily dose of up to 600 mg, Duzofarm is generally well tolerated.
Possible side effects:
    headache, sleep disturbances, dizziness;
    decreased appetite, diarrhea, pain in the epigastric region, ulcers of the gastric mucosa, intestinal colic, nausea, vomiting, a reversible increase in the activity of liver enzymes;
    allergic reactions.

Overdose

In case of overdose, it is possible to increase the severity of side effects, the appearance of anxiety, the development of bradycardia and ventricular arrhythmias, and a decrease in blood pressure.
There is no specific antidote. Overdose treatment methods include gastric lavage, intake of activated charcoal and laxatives, and symptomatic therapy.

Special instructions

At the beginning of treatment, patients should be closely monitored to control the reactions of individual drug tolerance. It is also necessary to monitor blood pressure in patients with a tendency to hypotension.
Patients with celiac disease (gluten enteropathy) should take into account that the drug contains wheat starch.
Influence on the ability to drive vehicles and complex mechanisms
According to the instructions, Duzofarm does not adversely affect psychophysical reactions and the ability to drive vehicles.

Application during pregnancy and lactation

Duzofarm does not have a teratogenic effect, however, special studies on the safety of its use in pregnant women have not been conducted. In this regard, the drug can be prescribed only in cases where the expected benefit outweighs the potential risks.
It is not recommended to use the drug during breastfeeding.

Childhood use

Due to the lack of data on the safety and effectiveness of Duzofarm tablets are not used to treat patients under the age of 18 years.

Drug interactions

Naphtidrofuril enhances the antihypertensive effect of antihypertensive drugs. If necessary, their simultaneous use should be monitored more often blood pressure, especially at the beginning of treatment.
Terms and conditions of storage
Keep out of the reach of children, protected from light, in a dry place at temperatures up to 25 ° C.
The shelf life is 3 years.

Reviews about Duzofarm

Reviews about Duzofarm are mostly positive. Patients report a significant improvement in their condition. With diabetic retinopathy, swelling and pain are reduced. Patients who have suffered a stroke write that the drug helps restore lost functions, improves memory and sleep, and eliminates dizziness and headaches. Patients note the convenience of taking pills - without reference to meals.
However, there are also neutral reviews in which patients confirm the effectiveness of Duzofarm, but complain about the development of side effects, more often in the form of nausea and decreased appetite.

Terms of sell

You can buy Duzofarm without a prescription.